Liquid Dose Manufacturing CMO: Market Size & Forecast 2026

The global liquid dose manufacturing CMO market sits at approximately USD 48.0 billion in 2025 (base year), expanding to roughly USD 74.6 billion by 2032 on a 6.5% CAGR. Oral liquids (solutions, suspensions, syrups) dominate at 42% of the product mix, followed by sterile injectables at 28%. The market operates in a structurally tight balance: big pharma continues to divest captive manufacturing capacity and route it to third-party CDMOs, while biologics-driven sterile-liquid demand strains fill-finish infrastructure. Packaging cost inflation, regulatory complexity across FDA, EMA, and EU 2025/40 (PPWR), and Section 301 tariffs on Chinese-origin glass vials compound the landed-cost picture for buyers. > **Analyst Take.** The call is to dual-source sterile injectable capacity now, not after the next shortage. The consensus 6.5% CAGR masks a bifurcated market: oral liquids grow at 4-5% whil

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.